Gilead Sciences Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Gilead Sciences heeft een totaal eigen vermogen van $18.2B en een totale schuld van $23.4B, wat de schuld-eigenvermogensverhouding op 128.3% brengt. De totale activa en totale passiva bedragen respectievelijk $53.6B en $35.4B. De EBIT Gilead Sciences is $10.7B waardoor de rentedekking 17.2 is. Het heeft contanten en kortetermijnbeleggingen van $3.8B.

Belangrijke informatie

128.3%

Verhouding schuld/eigen vermogen

US$23.35b

Schuld

Rente dekkingsratio	17.2x
Contant	US$3.78b
Aandelen	US$18.20b
Totaal verplichtingen	US$35.38b
Totaal activa	US$53.58b

Recente financiële gezondheidsupdates

Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?

Jun 13

Recent updates

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

May 02

Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark

Apr 22

Gilead Sciences: Some Signs Of An Impending Bottom

Apr 22

Gilead Sciences: Realizing Financial Projections Is Key

Mar 20

Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77

Mar 13

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $12.3B ) GILD } overtreffen de korte termijn passiva ( $10.8B ).

Langlopende schulden: De kortetermijnactiva van GILD ( $12.3B ) dekken de langetermijnschulden ( $24.6B ) niet.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 107.5% ) GILD wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van GILD is de afgelopen 5 jaar gestegen van 114.6% naar 128.3%.

Schuldendekking: De schuld van GILD wordt goed gedekt door de operationele kasstroom ( 32% ).

Rentedekking: De rentebetalingen op de schuld van GILD worden goed gedekt door EBIT ( 17.2 x dekking).

Gilead Sciences Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?

Recent updates

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention Conference

Chief Medical Officer notifies of intention to sell stock

Gilead Sciences: My Worst Stock Move In 2024, And What I Learned From It

Chief Commercial Officer notifies of intention to sell stock

Upcoming dividend of US$0.77 per share

Gilead Sciences: Buy This Bargain Before It's Gone

Gilead’S Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Consensus EPS estimates fall by 21%

Second quarter dividend of US$0.77 announced

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Gilead's New Anti-Obesity Drug: The Real Reason Behind The 25% Stock Surge?

A Look At Gilead Sciences After Its Recent Weakness

Gilead Sciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia

Gilead Records Positive Phase III Results In HIV

Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial

Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?

Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver Disease

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study

Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

Consensus EPS estimates fall by 79%

First quarter dividend of US$0.77 announced

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark

Gilead Sciences: Some Signs Of An Impending Bottom

Consensus EPS estimates fall by 57%

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences: Realizing Financial Projections Is Key

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Chairman & CEO exercised options and sold US$1.0m worth of stock

Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven